Analysts Are Bullish on These Healthcare Stocks: ONCE, ACER

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spark Therapeutics (NASDAQ: ONCE) and Acer Therapeutics Inc (NASDAQ: ACER) with bullish sentiments.

Spark Therapeutics (NASDAQ: ONCE)

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Spark Therapeutics (NASDAQ: ONCE) today and set a price target of $103. The company’s shares closed yesterday at $73.09.

Piros observed:

“We rate Spark Therapeutics Overweight. ONCE focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. With lead candidate LUXTURNA, Spark has become the first company in the U.S. with an approval for an in-vivo gene therapy product. $103/share price target is determined by the sum of the risk-adjusted NPV for the after-tax and discounted value of the programs analyzed, the value of the hemophilia A program, a platform value for the remaining pipeline and YE18 cash.”

According to, Piros is ranked 0 out of 5 stars with an average return of -4.0% and a 46.0% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.

Currently, the analyst consensus on Spark Therapeutics is Moderate Buy and the average price target is $83.70, representing a 14.5% upside.

In a report issued on May 8, William Blair also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

Acer Therapeutics Inc (NASDAQ: ACER)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Acer Therapeutics Inc (NASDAQ: ACER), with a price target of $50. The company’s shares closed yesterday at $18.98.

Selvaraju noted:

“We reiterate our Buy rating and 12-month price target of $50.00 on ACER shares.”

According to, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -3.5% and a 39.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

Acer Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $60.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.